Cargando...
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis. Upadacitinib is a nonsensitive substrate for metabolism by cytochrome P450 3A enzymes. This open‐label, single‐dose, multicenter study a...
Gardado en:
| Publicado en: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766976/ https://ncbi.nlm.nih.gov/pubmed/30973649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1414 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|